EGFR and non-small cell lung carcinoma: Leptomeningeal metastases (LMs) occur in 3.4%–3.8% of non-small cell lung cancer (NSCLC) patients and are more common (9.4%) in patients whose tumors carry epidermal growth factor receptor (EGFR) mutations, even during EGFR-TKI treatment (1–3).